26/04/2021 Date Journal Title Study type Country Authors Link Trial identifier Intervention Main question https://www.thelancet.c To evaluate the efficacy of the Inhaled budesonide in the treatment of early om/journals/lanres/artic Lancet Ramakrishnan S., inhaled glucocorticoid widely used inhaled glucocorticoid 9‐Apr‐21 COVID 19 (STOIC): a phase 2, open‐label, RCT 2 phase UK le/PIIS2213‐ NCT04416399 Respir Med. et al. budesonide budesonide in individuals with early randomised controlled trial 2600(21)00160‐ COVID‐19 in the community. 0/fulltext https://www.thelancet.c Efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine post‐hoc analysis of the efficacy of om/journals/lancet/artic against SARS‐CoV‐2 variant of concern 202012/01 Emary K.R.W., et ChAdOx1 nCoV 19 the adenoviral vector vaccine, 30‐Mar‐21 Lancet vaccine UK le/PIIS0140‐ NCT04400838 (B.1.1.7): an exploratory analysis of a randomised al (AZD1222) vaccine ChAdOx1 nCoV‐19 (AZD1222), 6736(21)00628‐ controlled trial against the variant B.1.1.7. 0/fulltext Methylprednisolone or dexamethasone, which https://bmcinfectdis.bio To assess the effectiveness of BMC one is superior corticosteroid in the treatment of medcentral.com/articles IRCT20200204046 Methylprednisolone methylprednisolone treatment 10‐Apr‐21 Infectious RCT Iran Ranjbar B hospitalized COVID‐19 patients: a triple‐blinded /10.1186/s12879‐021‐ 369N1 or dexamethason versus dexamethasone for Diseases randomized controlled trial 06045‐3 hospitalized COVID‐19 patients. Two phase 1 and phase 2 randomized, Immunogenicity and Safety of a SARS-CoV-2 https://www.medrxiv.or To report the immunogenicity and double‐ NCT04758273 Inactivated Vaccine (KCONVAC) in Healthy g/content/10.1101/2021 safety of a SARS‐CoV‐2 inactivated 8‐Apr‐2021 MedRxiv blind, and China Pan H et al AND KCONVAC Adults: Two Randomized, Double-blind, and .04.07.21253850v1.full.p vaccine, KCONVAC, in healthy placebo‐ NCT04756323 Placebo-controlled Phase 1/2 Clinical Trials df adults. controlled trials of KCONVAC INTERIM REPORT: SAFETY AND Interim https://www.medrxiv.or IMMUNOGENICITY OF AN INACTIVATED To evaluate safety parameters and analysis of a g/content/10.1101/2021 1‐Apr‐2021 MedRxiv VACCINE AGAINST SARS-COV-2 IN Chile Bueno SM et al NCT04651790 CoronaVac immunogenicity against SARS‐CoV‐2 multicenter .03.31.21254494v1.full.p HEALTHY CHILEAN ADULTS IN A PHASE 3 after immunization with CoronaVac phase 3 CT df CLINICAL TRIAL To assess the effect of oral Ivermectin treatment, which has been associated with iota‐ carrageenan in repeated doses A RANDOMIZED TRIAL - INTENSIVE https://www.medrxiv.or through the nasal and TREATMENT BASED IN IVERMECTIN AND g/content/10.1101/2021 Ivermectin / oral topical route, on the 30‐Mar‐2021 MedRxiv IOTA-CARRAGEENAN AS PRE-EXPOSURE RCT Argentina Chahla RE et al NCT04701710 .03.26.21254398v1.full.p IotaCarrageenan appearance and eventual PROPHYLAXIS FOR COVID- 19 IN df progression of COVID‐19 disease in HEALTHCARE AGENTS a healthy population that are exposed to it and have a higher risk of contagion of SARS‐ COV‐2 To assess the use of a nasal spray Efficacy of a nasal spray containing Iota‐ https://www.medrxiv.or Nasal spray containing containing I‐C in the prophylaxis of Carrageenan in the prophylaxis of COVID‐ 19 CARR‐COV2 Trial g/content/10.1101/2021 Iota‐Carrageenan (I‐C) 15‐Apr‐2021 MedRxiv RCT Argentina NCT04521322 COVID‐19 in hospital personnel in hospital personnel dedicated to patients Group collaborators .04.13.21255409v1.full.p or placebo for 21 dedicated to care of COVID‐19 df days. care with COVID‐19 disease patients to report the occurrence of https://www.medrxiv.or Performance of vaccination with CoronaVac symptomatic COVID‐19 in a cohort preliminary g/content/10.1101/2021 15‐Apr‐2021 MedRxiv in a cohort of healthcare workers (HCW) ‐ Brazil De Faria E et al NA CoronaVac of healthcare workers (HCW) report .04.12.21255308v1.full.p vaccinated with CoronaVac and to preliminary report df estimate its effectiveness. RBD‐specific polyclonal F(ab )2 fragments of To analyze the safety and efficacy of equine antibodies in patients with moderate to https://www.ncbi.nlm.ni EClinicalMedi Equine poly‐ clonal specific anti SARS‐COV‐2 EpAbs in 8‐Apr‐2021 severe COVID‐19 disease: A randomized, RCT Argentina Lopardo et al h.gov/pmc/articles/PMC NCT04494984 cine antibodies (EpAbs) hospitalized patients with mod‐ multicenter, double‐blind, placebo‐controlled, 8037439/pdf/main.pdf erate and severe COVID‐19 disease adaptive phase 2/3 clinical trial Diphenhydramine Compound (Diphenhydramine + Quaternary ammonium compounds Int J of Effect of Ammonium Chloride in addition to https://pubmed.ncbi.nl Ammonium Chloride) have been demonstrated to have 12‐Apr‐2021 Infectious standard of care in outpatients and hospitalized RCT Iran Siami Z et al NA m.nih.gov/33878462/ plus standard of care antiviral effects and may be of use Diseases COVID‐19 patients: a randomized clinical trial or Diphenhydramine against SARS‐CoV‐2 infections. alone and standard of care groups To determine any possible effects and safety concerns of the two most https://www.nature.co Scientific Role of interferon therapy in severe COVID‐19: promising exogenously 13‐Apr‐2021 RCT Iran Darazam IA et al m/articles/s41598‐021‐ NCT04343768 IFNβ1a and IFNβ1b reports the COVIFERON randomized controlled trial administrable IFNs on the course 86859‐y and outcomes of patients hospitalized with severe COVID‐19. Peginterferon Lambda‐1a for treatment of To evaluate the efficacy of Lambda https://pubmed.ncbi.nl Peginterferon Lambda‐ 30‐Mar‐2021 Nature Comm outpatients with uncomplicated COVID‐19: a RCT USA Jagannathan P et al NCT04331899 in reducing the duration of viral m.nih.gov/33785743/ 1a randomized placebo‐controlled trial shedding in outpatients. https://www.thelancet.c Safety and immunogenicity of SARS‐CoV‐2 The Lancet om/journals/laninf/articl recombinant protein vaccine formulations in healthy Vaccine trial Safety and imunogenicity of CoV2 preS 19‐Apr‐21 Infectious Multinational Goepfert et al. e/PIIS1473‐ NCT04537208 CoV2 preS dTM vaccine adults: a randomised, placebo‐controlled, dose‐ranging phase I/II dTM vaccine Disease study 3099(21)00147‐ X/fulltext https://www.thelancet.c Safety and immunogenicity of an MF59‐ The Lancet om/journals/laninf/articl adjuvanted spike glycoprotein‐clamp vaccine for Vaccine trial MF59‐adjuvanted Safety and imunogenicity of MF59‐ 19‐Apr‐21 Infectious Australia Chappell et al. e/PIIS1473‐ NCT04495933 SARS‐CoV‐2: a randomised, double‐blind, placebo‐ phase I subunit vaccine adjuvanted subunit vaccine Disease 3099(21)00200‐ controlled, phase 1 trial 0/fulltext ZF2001 Vaccine ‐ protein subunit Safety and immunogenicity of a recombinant vaccine against COVID‐ To assess the safety and https://www.sciencedire The Lancet tandem‐repeat dimeric RBD‐based protein 19 using a dimeric immunogenicity of this vaccine, ct.com/science/articleS1 24‐Mar‐21 Infectious subunit vaccine (ZF2001) against COVID‐19 in vaccine ‐ pha China ShilongYang, et al. 445194 and NCT044 form of the receptor‐ ZF2001, and determine the 473309921001274/pii/? Diseases adults: two randomised, double‐blind, placebo‐ binding domain (RBD) appropriate dose and schedule for via%3Dihub controlled, phase 1 and 2 trials of the SARS‐CoV‐2 an efficacy study. spike protein as the antigen Clinical effectiveness of drugs in hospitalized https://journals.sagepub To assess the clinical effectiveness 25‐Mar‐21 dvances in Resp patients with COVID‐19: a systematic review and meta‐analysis Mexico Zuñiga RAA, et al. .com/doi/10.1177/1753 NA ne, lopinavir, ritonavir, of drugs used in hospitalized meta‐analysis 4666211007214 patients with COVID‐19 infection. Effect of Helmet Noninvasive Ventilation vs High‐ To assess whether helmet Flow Nasal Oxygen on Days Free of Respiratory https://jamanetwork.co noninvasive ventilation can increase 25‐Mar‐21 JAMA Support in Patients With COVID‐19 and Moderate RCT International Domenico Luca Griecom/journals/jama/fullarti NCT04502576 oxygen the days free of respiratory support to Severe Hypoxemic Respiratory Failure The cle/2778088 in patients with COVID‐19 compared HENIVOT Randomized Clinical Trial with high‐flow nasal oxygen alone. Effect of Intermediate‐Dose vs Standard‐Dose To evaluate the effects of Prophylactic Anticoagulation on Thrombotic https://jamanetwork.co intermediate‐dose vs standard‐dose Events, Extracorporeal Membrane Oxygenation 18‐Mar‐21 JAMA RCT Iran SPIRATION Investigatom/journals/jama/fullarti NCT04486508 dard prophylactic antico prophylactic anticoagulation among Treatment, or Mortality Among Patients With cle/2777829 patients with COVID‐19 admitted to COVID‐19 Admitted to the Intensive Care Unit the intensive care unit (ICU) The INSPIRATION Randomized Clinical Trial Safety and immunogenicity of an inactivated https://www.thelancet.c SARS‐CoV‐2 vaccine, BBV152: interim results om/journals/laninf/articl To evaluate the safety and Lancet Infect Vaccine trial BBV152 (Bharat 8‐Mar‐2021 from a double blind, randomised, mulcentre, India Ella R., et al. e/PIIS1473‐ NCT04471519 immunogenicity of an inactivated Dis Phase II Biotech) vaccine phase 2 trial, and 3‐month follow‐up of a double‐ 3099(21)00070‐ SARS‐CoV‐2 vaccine, BBV152. blind, randomised phase 1 trial 0/fulltext Effect of Ivermectin on Time to Resolution of https://jamanetwork.co To determine whether ivermectin is RCT Phase Lopez‐Medina E., 4‐Mar‐2021 JAMA Symptoms Among Adults With Mild COVID‐19A Colombia/USA m/journals/jama/fullarti NCT04405843 Ivermectin an efficacious treatment for mild III et al. Randomized Clinical Trial cle/2777389 COVID‐19. To assess safety and efficacy of sarilumab, an interleukin‐6 receptor https://www.thelancet.c inhibitor, in patients with severe Sarilumab in patients admitted to hospital with om/journals/lanres/artic (requiring supplemental oxygen by Lancet Respir RCT Phase 4‐Mar‐2021 severe or crical COVID 19: a randomised, International Lescure FX., et al. le/PIIS2213‐ NCT04327388 Sarilumab nasal cannula or face mask) or Med III double blind, placebo‐controlled, phase 3 trial 2600(21)00099‐ critical (requiring greater 0/fulltext supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID‐19.